NCT05772520 — Plaque Psoriasis trial site landscape

Public-registry site landscape for NCT05772520, “The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis”, a Plaque Psoriasis study sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05772520 (registry record)
Study title	The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Official title	A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of TLL018 in Participants With Moderate-to-severe Plaque Psoriasis
Sponsor	Hangzhou Highlightll Pharmaceutical Co., Ltd
Condition(s)	Plaque Psoriasis
Phase	PHASE2
Listed sites	35
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT05772520.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05772520 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →